Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 8/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430301 | 0.80 | MPO (0.38) | MPOSLC9A1KEAP1SLC2A1ALDH1A1 | |
| SCHEMBL19819749 | 0.78 | MPO (0.42) | ADORA3MPOALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL17658845 | 0.78 | MPO (0.59) | MPOALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL17459798 | 0.77 | HTT (0.42) | ADORA3ADORA1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL18081416 | 0.77 | LMNA (0.37) | ADORA3ADORA1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL19836555 | 0.77 | NPC1 (0.38) | ADORA3ADORA1ALDH1A1CYP2C19SMN1; SMN2 | |
| SCHEMBL18293606 | 0.76 | MPO (0.56) | MPOALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL25082278 | 0.76 | CDK9 (0.36) | ADORA3ADORA1MPOCYP2C19 | |
| SCHEMBL15341875 | 0.76 | ADORA3 (0.38) | ADORA3ADORA1CYP2C19KDM5AKDM4C | |
| SCHEMBL23996985 | 0.76 | ESR1 (0.38) | ADORA3ADORA1ALDH1A1CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114357-A1 | BIFUNCTIONAL PROTAC AND MOLECULAR GLUE COMPOUNDS AND METHODS OF USE THEREOF | BAERENKRAFT THERAPEUTICS, LLC | 2025-04-10 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| WO-2020132582-A1 | STING AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| CN-108264512-A | Nitrogenous fused heterocyclic compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2018-07-10 | — | — | CN | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124669-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ADORA3 257/4885ADORA1 106/4885MPO 1854/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | ADORA3 77/4885ADORA1 85/4885MPO 1444/4885 |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | ADORA3 4244/4885ADORA1 3713/4885MPO 895/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ADORA3 260/4885ADORA1 106/4885MPO 1893/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | ADORA3 257/4885ADORA1 106/4885MPO 1854/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | ADORA3 1483/4885ADORA1 690/4885MPO 670/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ADORA3 2176/4885ADORA1 1295/4885MPO 1755/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ADORA3 2193/4885ADORA1 1338/4885MPO 1788/4885 |
| US-20110124669-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | ADORA3 257/4885ADORA1 106/4885MPO 1854/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ADORA3 253/4885ADORA1 104/4885MPO 1840/4885 |
| US-20250114357-A1 | BIFUNCTIONAL PROTAC AND MOLECULAR GLUE COMPOUNDS AND METHODS OF USE THEREOF | F12, RPP30, RPS27A | ADORA3 800/4885ADORA1 1702/4885MPO 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.